Spots Global Cancer Trial Database for stage iii oropharyngeal squamous cell carcinoma ajcc v7

Every month we try and update this database with for stage iii oropharyngeal squamous cell carcinoma ajcc v7 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer	NCT01810913	Oropharyngeal p... Stage III Hypop... Stage III Laryn... Stage III Oral ... Stage III Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Oral C... Stage IV Oropha...	Atezolizumab Biospecimen Col... Cetuximab Cisplatin Computed Tomogr... Docetaxel Intensity-Modul... Laboratory Biom... Magnetic Resona... Quality-of-Life...	18 Years -	National Cancer Institute (NCI)
Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma	NCT03799445	Clinical Stage ... Clinical Stage ... Human Papilloma... Oropharyngeal B... Pathologic Stag... Pathologic Stag... Posterior Tongu... Soft Palate Squ... Stage III Oroph... Stage IVA Oroph... Tonsillar Squam...	Intensity-Modul... Ipilimumab Nivolumab Quality-of-Life... Questionnaire A...	18 Years -	M.D. Anderson Cancer Center
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer	NCT01810913	Oropharyngeal p... Stage III Hypop... Stage III Laryn... Stage III Oral ... Stage III Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Oral C... Stage IV Oropha...	Atezolizumab Biospecimen Col... Cetuximab Cisplatin Computed Tomogr... Docetaxel Intensity-Modul... Laboratory Biom... Magnetic Resona... Quality-of-Life...	18 Years -	National Cancer Institute (NCI)
Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer	NCT03601507	CDKN2A-p16 Posi... HPV Positive Or... Stage I Orophar... Stage II Oropha... Stage III Oroph... Stage IVA Oroph...	Alpelisib Laboratory Biom... Pharmacodynamic... Therapeutic Con...	-	University of Arizona
Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer	NCT02567422	Head and Neck C... Head and Neck S... Stage III Hypop... Stage III Laryn... Stage III Oral ... Stage III Oroph... Stage III Sinon... Stage IV Hypoph... Stage IV Laryng... Stage IV Oral C... Stage IV Oropha... Stage IV Sinona...	Berzosertib Cisplatin Computed Tomogr... Laboratory Biom... Magnetic Resona... Positron Emissi... Radiation Thera...	18 Years -	National Cancer Institute (NCI)
Intensity-Modulated Proton Beam Therapy or Intensity-Modulated Photon Therapy in Treating Patients With Stage III-IVB Oropharyngeal Cancer	NCT01893307	Stage III Oroph... Stage IVA Oroph... Stage IVB Oroph...	Intensity-Modul... Intensity-Modul... Laboratory Biom... Photon Beam Rad... Proton Beam Rad... Quality-of-Life...	18 Years -	M.D. Anderson Cancer Center
Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer	NCT02567422	Head and Neck C... Head and Neck S... Stage III Hypop... Stage III Laryn... Stage III Oral ... Stage III Oroph... Stage III Sinon... Stage IV Hypoph... Stage IV Laryng... Stage IV Oral C... Stage IV Oropha... Stage IV Sinona...	Berzosertib Cisplatin Computed Tomogr... Laboratory Biom... Magnetic Resona... Positron Emissi... Radiation Thera...	18 Years -	National Cancer Institute (NCI)
Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer	NCT03144778	Stage II Oropha... Stage III Oroph... Stage IVA Oroph...	Durvalumab Tremelimumab	18 Years -	M.D. Anderson Cancer Center
Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer	NCT02567422	Head and Neck C... Head and Neck S... Stage III Hypop... Stage III Laryn... Stage III Oral ... Stage III Oroph... Stage III Sinon... Stage IV Hypoph... Stage IV Laryng... Stage IV Oral C... Stage IV Oropha... Stage IV Sinona...	Berzosertib Cisplatin Computed Tomogr... Laboratory Biom... Magnetic Resona... Positron Emissi... Radiation Thera...	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: